Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival
| Autor: | Nicole Margo Grogan, Najla Itani, Sarah L. Mott, Sneha Phadke |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Adult Cancer Research medicine.medical_specialty Time Factors Adolescent Receptor ErbB-2 Physical examination Breast Neoplasms Disease Metastasis 03 medical and health sciences Young Adult 0302 clinical medicine Breast cancer Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Biomarkers Tumor Humans Breast Stage (cooking) Medical diagnosis Mastectomy Neoplasm Staging Retrospective Studies medicine.diagnostic_test business.industry Proportional hazards model Retrospective cohort study Middle Aged medicine.disease Survival Analysis 030104 developmental biology Oncology Receptors Estrogen Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Neoplasm Recurrence Local business Receptors Progesterone |
| Zdroj: | Clinical breast cancer. 20(3) |
| ISSN: | 1938-0666 |
| Popis: | Breast cancer (BC) patients undergoing surveillance often fear recurrence. Given that routine imaging is not recommended, recognizing metastatic disease early requires a knowledge of recurrence patterns. The aim of this study was to analyze the most common presentations of metastatic disease.A retrospective review was conducted of patients who were initially diagnosed with early-stage BC and who later developed metastatic disease. Data collected included method of metastatic disease diagnosis, types of symptoms at diagnosis, and survival. Chi-square tests as well as logistic and Cox regression models were used.Metastatic diagnoses were made from reported symptoms in 77.6% of patients, clinical examination in 3.2%, and 7.8% incidentally on imaging. Among those with symptoms, musculoskeletal pain was the most common (33.7%) and was more frequently noted at scheduled (48.9%) compared to acute-care visits (26.0%, P .01). Receptor status was associated with nervous system symptoms at metastasis (P = .01), with higher odds of nervous system symptoms in triple-negative (odds ratio = 3.02) compared to estrogen receptor/progesterone receptor-positive, HER2In this retrospective study, patients who presented with symptoms did not have shorter survival compared to those who were diagnosed in other ways. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect